Laurel Wealth Advisors (North Carolina)’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-6
Closed -$4K – 596
2022
Q2
$4K Hold
6
– – ﹤0.01% 475
2022
Q1
$4K Hold
6
– – ﹤0.01% 513
2021
Q4
$4K Hold
6
– – ﹤0.01% 515
2021
Q3
$4K Hold
6
– – ﹤0.01% 517
2021
Q2
$3K Hold
6
– – ﹤0.01% 632
2021
Q1
$3K Sell
6
-15
-71% -$7.3K ﹤0.01% 573
2020
Q4
$10K Buy
21
+6
+40% +$3.24K ﹤0.01% 417
2020
Q3
$8K Hold
15
– – ﹤0.01% 400
2020
Q2
$9K Hold
15
– – ﹤0.01% 387
2020
Q1
$7K Buy
+15
New +$6.19K ﹤0.01% 391

Other funds holding REGN

Laurel Wealth Advisors (North Carolina)'s REGN Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 6 shares — an estimated $4K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in REGN in Q1 2020 and held it in 10 quarters. The position peaked at $10K in Q4 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 6 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $4K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 10 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Regeneron Pharmaceuticals position peaked at $10K in Q4 2020.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.